A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics

被引：23

作者：

Franconi, Flavia ^{[1
,2
]}

Carru, Ciriaco ^{[3
]}

Spoletini, Ilaria ^{[4
]}

Malorni, Walter ^{[5
]}

Vella, Stefano ^{[5
]}

Mercuro, Giuseppe ^{[6
]}

Deidda, Martino ^{[6
]}

Rosano, Giuseppe ^{[4
]}

机构：

[1] Univ Sassari, INBB Osilo Sassari, Ctr Biotechnol Dev & Biodivers Res, Via Muroni 23, I-07100 Sassari, Italy

[2] Univ Sassari, INBB Osilo Sassari, Dept Pharmacol, I-07100 Sassari, Italy

[3] Univ Sassari, Dept Biomed Sci, Sassari, Italy

[4] IRCCS San Raffaele Pisana, Dept Med Sci, Ctr Clin & Basic Res, Pisana, Italy

[5] Ist Super Sanita, Dept Drug Res & Med Evaluat, Rome, Italy

[6] Univ Cagliari, Dept Cardiovasc & Neurol Sci, Cagliari, Italy

来源：

THERAPEUTIC DELIVERY | 2011年 / 2卷 / 11期

关键词：

D O I：

10.4155/TDE.11.117

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacological outcomes depend on many factors, with many of them being sexually dimorphic. Thus, physiological gender/sex (GENS) differences can influence pharmacokinetics, pharmacodynamics and, thus, bioavailability and resulting in efficacy of treatment, meaning GENS differences should be an important consideration in therapeutics. In particular, drug response can change according to different hormonal environments. Therefore, GENS-specific differences have a particular clinical relevance in terms of drug delivery, especially for those substances with a narrow therapeutic margin. Since adverse effects are more frequent among women, safety is a key issue. Overall, the status of women, from a pharmacological point of view, is often different and less studied than that of men and deserves particular attention. Further studies focused on women's responses to drugs are necessary in order to make optimal pharmacotherapeutic decisions.

引用

页码：1437 / 1453

页数：17